ABSTRACT Numerous monoclonal antibodies (MAbs) that recognize and neutralize infectious pathogens have been isolated and developed over the years. The fact that infectious diseases can involve large populations of infected individuals is an important factor that has motivated the search for both cost-effective and scalable methods of antibody production. The current technologies for production of antibodies in plants allow for very rapid expression and evaluation that can also be readily scaled for multikilogram production runs. In addition, recent progress in manipulating glycosylation in plant production systems has allowed for the evaluation of antibodies containing glycans that are nearly homogeneous, are mammalian in structure, and have enhanced neutralizing capabilities. Among the anti-infectious disease antibodies that have been produced in plants are included those intended for prevention or treatment of anthrax, Clostridium perfringens, Ebola virus, human immunodeficiency virus, herpes simplex virus, rabies, respiratory syncytial virus, staphylococcal enterotoxin, West Nile virus, and tooth decay. Animal and human efficacy data for these MAbs are discussed.
INTRODUCTION
Production and evaluation of monoclonal antibodies (MAbs) produced in plants to combat infectious diseases (IDs) has been ongoing for almost 20 years (1) . With the recent FDA approval of the first plant-derived biologic (2) , development of rapid manufacturing technology (3) , and the capability of producing MAbs with homogenous mammalian glycosylation (4), a wave of infectious disease (and other) MAbs that are plant-derived are expected to enter clinical trials in the next several years. This review is intended to summarize the results of research on plant-derived MAbs to infectious pathogens that have completed animal or clinical studies.
PRODUCTION OF MAbs IN PLANTS Rationale for Manufacturing ID MAbs in Plants
There are a number of advantageous characteristics of plant systems for production of anti-infective antibodies. One in particular has to do with the ease with which complex, multicomponent isotypes can be assembled (1, 5) . The most structurally complex type of antibody, a secretory immunoglobulin A (sIgA) consisting of four different chains, can be assembled in plants to produce functional, protease-resistant antibody molecules appropriate for use in environments where other types of antibodies are not found (e.g., the gastrointestinal tract) (1) . Since mucosal surfaces are often the site of entry of infectious pathogens (6) , the technology that can provide an appropriate type of antibody isotype for that environment could be uniquely suited for combating infectious diseases. Moreover, the use of antibodies at mucosal surfaces emphasizes preventive strategies that would deny entry to pathogens, rather than postexposure or therapeutic strategies. Preventive applications of antibodies inherently require a much larger scale of production due to a requirement for repeated dosing.
Because preventive strategies ordinarily involve larger populations, an appropriate unit cost for a preventative antibody can be achieved at a sufficiently large production scale (7, 8) . The ability to scale up production without incurring excessive capital requirements or a change in production methods is a hallmark of production in plants (7) .
Transgenic Technologies for Plant-Based MAb Production
The first technology that was employed to express an antibody in a plant involved the transfer of recombinant selectable vectors into small pieces of leaf ("leaf discs") (9) by use of Agrobacterium tumefaciens infection as the transformation vehicle (1, 5) . The early results of plant expression of a MAb to an infectious pathogen (1) demonstrated a number of principles about the variety of MAb isotypes that can be produced in plants as well as the characteristics and localization of those antibodies within the plant leaf (1) . Early experiments exploring the capabilities of plants for expressing, assembling, and secreting complex immunoglobulins used a plant transformation technology that was almost entirely based on regeneration of plants from infected plant cells carrying the antibody-encoding cDNAs (5). Infection was accomplished using engineered Agrobacterium that could selectively deliver the immunoglobulin-encoding DNAs to the plant cell nucleus (9) . This process of creating fertile transgenic plants suffered from the significant period of time required for regeneration (∼1 year) but did benefit from the ability to cross-pollinate the resulting plants to derive progeny that produced a desired combination of immunoglobulin chains (1, 5) . In the first set of transgenic experiments, plants expressing IgG (γ) or Ig(κ) chains were cross-pollinated to produce progeny expressing assembled antibody (5) . These IgGs possessed the same specificity when compared to the original mammalian cell-derived MAb. In subsequent experiments, the IgG constant region was replaced with a hybrid constant region consisting of both IgG and IgA components (1) . When these hybrid heavy chain plants were crossed with plants expressing kappa, J chain, and secretory component, an assembled sIgA was produced. Microscopic examination of antibody accumulation showed that specific cell types, predominantly bundle sheath cells, were responsible for the relatively high level of sIgA accumulation in these plants.
Overall, the results demonstrated that a variety of immunoglobulin isotypes could be expressed in plants to yield complex, functional antibodies and that multiple immunoglobulin chains could be assembled into antibodies by stepwise cross-pollination of plants containing immunoglobulin genes. Moreover, the use of a hybrid constant region could result in assembly and high-level production of a class of antibody that is not ordinarily observed from mammalian cell culture. Perhaps due to their inherent biochemical stability, the hybrid sIgA accumulated in these plants to levels that are not ordinarily observed in transgenics (∼5% of extractable protein).
Transient Technologies for Plant-Based MAb Production
Recent plant-based manufacturing techniques have been aimed at deriving a higher level of expression and, importantly, a short time frame to generate MAb. One commercially viable technique, referred to as "magnifection," involves transient expression of the MAb wherein the infection of the cell is accomplished after introducing several pro-vectors into Agrobacterium tumefaciens that can deliver noncompeting viral components (derived from tobacco mosaic virus and potato virus X) as well as the MAb genes to plant cells (3, 10) . In this sense, Agrobacterium is the vehicle for primary infection of the plant, whereas the ultimately recombined, functional viral replicon provides cell-to-cell spread, amplification, and high expression (Fig. 1) . The technology appears to be the most rapid path from genes to full-length, assembled MAb, i.e., 14 days from gene delivery to purified MAb (10) . The manufacturing technology can easily accommodate hundreds of grams per month for preclinical and clinical studies as well as commercial scale (7, 8) . Because antibody drug development has evolved into a highly iterative process where sequential modifications are introduced into candidate molecules and evaluated for changes in efficacy, the shortened time frame to multi-gram-level production may accelerate this process greatly.
Technologies for Controlling MAb N Glycosylation
Recently, transgenic technology has been used to generate plants that yield MAbs with homogenous N glycosylation patterns (4) (Fig. 2) . Specifically, using RNA interference technology, Nicotiana benthamiana plants have been generated that have dramatically reduced xylosyl or fucosyl transferase enzymatic activities (ΔXF) (11) . Antibodies expressed in this transgenic plant contain a single dominant N-glycan species consisting of biantennary N-glycans with terminal N-acetylglucosamine on both branches (GnGn) that shows significantly enhanced binding to FcγRIIIa, as has been observed with other nonfucosylated MAbs derived from other sources (11) . A plant-derived anti-human immunodeficiency virus (anti-HIV) antibody produced in these plants was the first example of using glycoengineering to improve the antiviral activity of a MAb (11) .
Introduction of the β-1,4-galactosyl transferase gene into this ΔXF plant background resulted in a fully galactosylated and relatively homogeneous N-glycosylation. These MAbs (11) consisted of two broadly neutralizing anti-HIV MAbs (2G12, 4E10) and displayed improved virus neutralization potency when compared with other glycoforms produced in plants and in CHO cells.
The final sugar addition in many mammalian glycans is sialylation (12) . Terminal α-2,6-sialic acid is an important mediator of diverse biological activities. In particular, sialylation appears to play a crucial role in the efficacy of intravenous immunoglobulin for autoimmune diseases (13, 14, 15) . Plants do not make sialic acid; however, the entire biosynthetic pathway for antibody sialylation has been incorporated into ΔXF Nicotiana plants (12) . IgG antibodies expressed in the sialo-engineered plants have a significant percentage of molecules with α-2,6-sialic acid termini that can exceed the percentage observed in intravenous immunoglobulin.
In sum, the glycoengineering that has been accomplished to date has provided a variety of glycoforms with either enhanced biological activity (e.g., antiviral) or fully human glycans.
PLANT-DERIVED MAbs AGAINST ID TARGETS
To date, a variety of plant-produced MAbs have been described. The focus here is on MAbs that have been tested for efficacy in animals or humans (Table 1) .
Dental Caries MAbs
Clinical evaluation of the plant-produced Guy's 13 sIgA/ G has been performed (16) . In an initial trial, patients received 9 days of chlorhexidine treatment to eliminate Streptococcus mutans from their oral cavities followed by two treatments per week for 3 weeks with Guy's 13 sIgA/G, saline, or control antibody. Patients treated with the plant-derived Guy's 13 had no recolonization with S. mutans (n = 4), whereas patients treated with saline (n = 4) or control antibody (n = 3) were all recolonized. All treatments in this study were performed in a dental clinic. In a subsequent trial testing home treatment, 56 eligible adults had 9 days of treatment with chlorhexidine and were randomized equally to a group receiving 0, 2, 4, or 6 topical applications of plantproduced Guy's 13 followed by 6, 4, 2, or 0 applications of placebo, respectively, over a 3-week period. After 6 months, there were no significant differences in S. mutans levels by number of applications, relative to placebo. No adverse effects were observed during the study, and it was concluded that plant-produced Guy's 13 is safe but not effective at the frequency, concentration, and number of applications used in that study. However, subsequent clinical evaluation did define the effective parameters of administration. CaroRx, the commercial name for the plant-produced Guy's 13 anticaries MAb product, is intended for regular oral topical preventative administration. New clinical trials have indicated that this treatment can effectively eliminate decay-causing bacteria for up to 2 years (16, 17, 18, 19) . CaroRx has demonstrated efficacy and safety in a phase 2 clinical trial (www.planetbiotechnology.com/products. html) (20) .
Ebola Virus MAbs
Recent outbreaks in central Africa and concerns about weaponization highlight the lack of any vaccine or treatment for Ebola virus infection. A recent study focused on the role of antibody glycosylation in the development of an immunoprotectant for Ebola virus revealed potential advantages of plant production of MAbs against infectious pathogens (21) . An anti-Ebola glycoprotein (GP) MAb was produced in ΔXF Nicotiana plants, resulting in MAb with a highly homogenous distribution of N-glycoforms (90% GnGn) and lacking potentially immunogenic plant-specific β1,2 xylose and core α1,3 fucose. The MAb, h-13F6, recognizes the heavily glycosylated mucin-like domain of GP. h-13F6 does not neutralize in vitro, as assessed by inhibition of plaque formation, even in the presence of complement (21) , suggesting an important role for Fc-mediated effector functions in in vivo protection. The plant-derived h-13F6 was compared with h-13F6 produced in CHO cells in a lethal mouse Ebola virus challenge model. The plant-derived h-13F6 carrying N-glycans lacking fucose showed threefold-superior potency to h-13F6 with typical CHO glycosylation patterns (21) . Elimination of core fucose has been shown to dramatically improve antibody-dependent cellular cytotoxicity (ADCC) activity in vitro and in vivo through improved affinity for FcγRIII (22, 23, 24, 25) . Indeed, affinity analyses of the plant-and CHO-derived h-13F6 confirmed that elimination of core fucose from h-13F6 resulted in an improved affinity for FcγRIII. In total, these results suggested that ADCC is an important mechanism of protection by this MAb. Further studies have now been performed showing that a cocktail of 3 Nicotianaderived anti-Ebola GP MAbs (including h-13F6) can protect rhesus macaques from lethal challenge: 100% survival was observed when the MAbs were administered an hour after challenge and 67% survival when delivered 1 or 2 days postchallenge (26) . This study demonstrated a greater therapeutic window as well as reduced viral burden and level of disease compared to other therapeutics in development (26) .
HSV and HIV MAbs: Preventing Sexual Transmission
The earliest in vivo comparison study of a plantproduced and a cell culture-produced MAb involved a humanized anti-herpes simplex virus (anti-HSV) glycoprotein B antibody made in soybeans compared to the same MAb expressed in mammalian cell culture of Sp2/0 cells (27) . The comparative assays included diffusion and stability in mucus as well as prevention of vaginal transmission of genital herpes in the mouse. No significant difference was observed in these assays, and vaginal delivery of 10 μg of either MAb provided 100% protection against vaginal challenge with HSV type 2 (27) . A microbicide containing a cocktail of HSV and HIV MAbs is currently being evaluated for efficacy in the simian HIV nonhuman primate model and is expected to enter a clinical safety trial in 2014 (K. Whaley and F. Villinger, personal communication). A number of broadly neutralizing HIV MAbs have been produced in plants and evaluated on the basis of binding ability as well as structure (28, 29, 30, 31) . For example, one of the broadly neutralizing MAbs, 2G12, has been produced in transgenic maize plants (29) , and the HIV neutralization capability of the antibody is equal to or superior to that of the same antibody produced in CHO cells. 2G12 has also been transiently produced in the ΔXF Nicotiana line and was found to contain a relatively homogeneous N-glycan species without detectable xylose or α-1,3-fucose residues (4). In general, plant-derived 2G12 was indistinguishable from CHO-derived 2G12 with respect to electrophoretic properties as well as functional properties (i.e., antigen ASMscience.org/MicrobiolSpectrumbinding and HIV neutralization activity). In some cases, plant-produced HIV MAbs appear to have enhanced potency compared to CHO-produced MAbs. Fully galactosylated 4E10 (another broadly neutralizing MAb) and 2G12 were reported to be severalfold higher in neutralization potency than CHO-produced MAbs (11) . In addition, sialylated 2G12 exhibits in vitro HIV neutralization potency similar to that of other glycoforms derived from plants and CHO cells (12) . Other plant expression systems have been used to produce these MAbs as well: 4E10 has been produced in a transgenic tobacco rhizosection system (31) , and a fusion protein of the broadly neutralizing HIV MAb b12 and cyanovirin produced in transgenic tobacco increased HIV potency compared to b12 or cyanovirin alone (32) .
Rabies Virus MAbs
Since more than 10 million people annually receive rabies virus postexposure prophylaxis in the form of equine antirabies immunoglobulin or human antirabies immunoglobulin (HRIG), together with rabies vaccine (33) , there is a worldwide shortage of these immunoglobulins. The limited supply and the additional risk of adverse reactions associated with equine antirabies immunoglobulin have spurred the search for new MAbs. In addition, the high cost of HRIG has been a significant impediment in providing postexposure prophylaxis against rabies (34) . To address these limitations, transgenic plants have been used as an efficient production system for the expression of functional therapeutic antirabies MAbs (35) . In the first report of systemic administration of a plant-derived MAb to provide immunoprotection, a human antirabies MAb was purified from transgenic tobacco plants and characterized structurally and for its effectiveness in vivo (36) . The plantderived MAb was compared with an equivalent human MAb expressed in murine-human hybridoma cell lines (37, 38) and/or commercial HRIG for neutralization activity, protein stability, N-glycan processing, and the efficacy of rabies virus postexposure prophylaxis in exposed animals. The plant-derived MAb was as effective at neutralizing the activity of the rabies virus as the mammalian-derived antibody or HRIG. Due to the incorporation of an endoplasmic retention signal on the MAb heavy chain (to increase accumulation), the plant-derived MAb contained mainly oligomannose type N-glycans (90%) and had no potentially antigenic α(1,3)-linked fucose residues. The plant-derived MAb had a shorter serum half-life than mammalian cellderived MAb but was as efficient as HRIG for postexposure prophylaxis against rabies virus in hamsters, indicating that differences in N-glycosylation do not affect the efficacy of the antibody in this model (38) .
RSV MAbs
Synagis is the only MAb approved by the FDA for an ID indication and currently generates sales of greater than $1 billion/year. Although Synagis is an effective drug for respiratory syncytial virus (RSV) immunoprophylaxis in at-risk neonates, ongoing analyses on the pharmacoeconomics suggest that Synagis may not be cost-effective in actual use, nor even when its use is restricted very tightly to its labeled population (39, 40, 41, 42, 43, 44) . A less expensive RSV MAb could improve the pharmacoeconomics in neonates and open up additional markets; RSV is a significant cause of morbidity and mortality in the elderly as well as in hematopoietic stem cell transplant patients. Several RSV-neutralizing MAbs have been produced in Nicotiana using magnifection and have been tested in the cotton rat model of protective efficacy (80) . Synagis and the identical amino acid sequence expressed in Nicotiana were superior to other candidate MAbs and were essentially indistinguishable in terms of affinity, neutralization, and in vivo protection, providing greater than 100-fold reduction in viral lung titer when dosed at 5 mg/kg of body weight. The data also suggested that the Nicotiana-derived MAb was more potent therapeutically than Synagis, raising the possibility that enhanced ADCC conferred by the ΔXF Nicotiana N-glycans may be responsible for improved efficacy in an established RSV infection (80) .
WNV MAbs
West Nile virus (WNV) has in the past been responsible for outbreaks of mild illness in regions of Africa, the Middle East, Asia, and Australia. In the 1990s, however, the epidemiology of infection changed and new outbreaks in Eastern Europe were associated with higher rates of severe neurological disease (45) . In 1999, WNV entered North America, and since then, WNV has spread to all 48 of the lower United States as well as to parts of Canada, Mexico, the Caribbean, and South America. Because of the increased range, the number of human cases has continued to rise: in the United States between 1999 and 2008, 28,961 cases that reached clinical attention were confirmed and associated with 1,131 deaths (46) . The lack of effective and specific antiviral treatment for infection by WNV or other flaviviruses (47) has prompted the search for highly specific therapies, including MAbs. Although smallmolecule antiviral agents have been described with ac-tivity against WNV in vitro, efficacy in vivo has been limited (48) . A humanized murine MAb (Hu-E16) that binds to a highly conserved epitope on domain III (DIII) of the WNV envelope (E) protein has been described (49) . This MAb blocks viral fusion at low concentrations (50, 51) and has therapeutic activity in rodents even after WNV has entered the central nervous system (52, 53) . Magnifection has been used to produce high levels of the Hu-E16 MAb, which retained neutralizing activity and significant pre-and postexposure therapeutic activity in mice (54) . The therapeutic activity was virtually equivalent to that observed with mammalian cell culture-derived Hu-E16 with 80 to 90% survival when delivered 2 or 4 days postchallenge (54) .
MAbs to Bacterial Toxins Anthrax MAbs
Anthrax toxin-specific antibodies have previously been shown to provide passive protection against an anthrax challenge (55, 56, 57, 58) . These antibodies, generally against protective antigen, protect rats, guinea pigs, rabbits, and nonhuman primates when administered within a time frame of several hours before or after the exposure to inhalation anthrax (59, 60, 61, 62, 63, 64, 65, 66, 67, 68) . A transgenic Nicotiana-derived nonglycosylated MAb directed against protective antigen has been evaluated (68) . This antibody neutralized anthrax lethal toxin activity in vitro and protected mice from lethal intraperitoneal challenge with spores. The nonglycosylated MAb possessed superior efficacy (100% protection) against an aerosol challenge compared with the glycosylated form (40%) after a single 5-mg/kg of body weight intravenous administration in nonhuman primates. This was attributed to the shortened half-life observed with the glycosylated MAb. In general, the data demonstrate that the absence of Nlinked glycans does not affect the ability of this MAb to protect animals against a lethal spore challenge. The results also demonstrate that plant production is an appropriate technology for generating nonglycosylated MAbs and could be useful in meeting the production challenge involved in the treatment of inhalation anthrax in humans. An additional plant-derived immunotherapeutic utilized a recombinant fusion protein comprised of a fusion of a human receptor for anthrax toxins (capillary morphogenesis protein 2 [CMG2]) and the Fc of human IgG1, for long-circulating half-life and immune effector cell interaction (69) . CMG2-Fc, purified from tobacco plants, fully protected rabbits against a lethal challenge with Bacillus anthracis spores at a dose of 2 mg/kg of body weight administered at the time of challenge. Treatment with CMG2-Fc did not interfere with the development of the animals' own immunity to anthrax, as treated animals that survived an initial challenge also survived a rechallenge 30 days later (69) .
Clostridium perfringens ETX
Potential aggressors have shown interest in the biological weapons potential of C. perfringens, and the UN Special Commission identified it as having been developed and potentially weaponized in Iraq (70, 71) . Epsilon toxin (ETX) is the most potent of the C. perfringens toxins, with a mouse intravenous lethal dose of 100 ng per kg of body weight (72) . A previously identified mouse MAb, 4D7, with potent neutralizing activity (73) was chimerized with human constant regions and produced in the magnifection system. This MAb demonstrated 100% prophylactic and postexposure efficacy against challenge (F. Uzal and L. Zeitlin, unpublished data).
SEB
Staphylococcal enterotoxin B (SEB) is an extremely potent enterotoxin involved in a large proportion of cases of toxic shock syndrome as well as a very significant mediator of staphylococcal food poisoning (74, 75, 76) . Because of its extreme potency, current interest in SEB relates to its potential for use as a biowarfare or bioterrorism agent. There are currently no therapeutic options available for SEB exposure. SEB MAb production in the magnifection system resulted in very high levels of MAb accumulation (77) . A human-mouse chimeric MAb against SEB has now been shown to provide 100% protection in mouse lethal aerosol and systemic challenge models (C. Roy, L. Zeitlin, et al., unpublished data).
Plant-Produced MAbs for Purification of ID Antigens
MAbs specific for particular ID antigens have also been produced in plants to facilitate large-scale purification of the antigen for use as a vaccine. For example, a recombinant antibody specific for the HBsAg was purified from transgenic Nicotiana tabacum plants to test its ability to immunopurify a yeast rHBsAg to be putatively used as a vaccine in humans. The purification system was mainly based on recombinant protein A expanded bed adsorption chromatography, which has been widely used for MAb purification (78, 79) . In this chromatography, a strong interaction among the protein A and Fc fragments of the antibodies is normally produced, allowing high recovery and purity. Additionally, its main advantage is the capacity to be introduced as a primary recovery operation to handle unclarified materials, yielding a combination of clarification, concentration, and adsorptive purification in a single step. Further preclinical evaluation has demonstrated that the MAb readily interacts with cell surface HBsAgs and displays complement-dependent cytotoxicity in a manner that was similar to anti-HBs human immunoglobulins used clinically. This product is now being used in Cuba in the manufacturing of HBsAg for active immunization.
CONCLUSION
Since the early days of plant expression of antibodies (5), research into the application of the technology for preventing or treating infectious pathogens has resulted in established clinical efficacy in one case and fundamental proof of concept in others. In addition, the ability of plants to readily assemble antibodies that are appropriate for applications involving mucosal and topical surfaces derives from the various ways that different antibody components can be assembled as well as the fidelity of the endomembrane system of plants in efficiently assembling and secreting antibody molecules. Further, the ability to manufacture MAb with specific mammalian N-glycosylation patterns allows for customization of biological activity. Now that a plantderived biologic has found regulatory acceptance, the path to approval of novel antibody anti-infectives derived from plants should be straightforward. Whereas it remains to be seen the extent to which plant-derived antibody products will enjoy benefit of scale, the promise of a production system that can provide novel antiinfectives at low cost to a large market continues to drive research in the field.
